Clarient Breathes Life Into Lung Cancer Biz With Applied Genomics Buy
This article was originally published in The Gray Sheet
Executive Summary
Clarient is expanding its lung cancer business and gaining a pipeline of immunohistochemistry tests for lung, breast and ovarian cancers with its $17.6 million acquisition of Applied Genomics
You may also be interested in...
News In Brief
Speaker Boehner’s new policy director is AdvaMed’s Brett Loper
News In Brief
Speaker Boehner’s new policy director is AdvaMed’s Brett Loper
Research In Brief
Mammostrat: Results of a 1,812-patient study support the prognostic value of Clarient's test for risk-stratifying early-stage, tamoxifen-treated breast cancer, John Bartlett, University of Edinburgh, et al., write in a July 8 article published online by Breast Cancer Research. The researchers found that increased Mammostrat scores were significantly associated with reduced relapse-free survival and overall survival. Clarient expects to launch Mammostrat, gained through its acquisition of Applied Genomics, in the fourth quarter (1"The Gray Sheet" Jan. 4, 2010)